June 1, 2022
“Today’s announcement of U.S. Food and Drug Administration (FDA) clearance for the Abbott’s FreeStyle Libre® 3 expands the market for reliable and advanced technology care options for people impacted by diabetes. For nearly 25 years, Breakthrough T1D has been at the forefront of funding research into continuous glucose monitors and other tech devices to help ease the day-to-day burdens of maintenance, and we are excited to see the continued growth and advancements in the field.”
-JDRF
